articleJournal of Clinical InvestigationJun 6, 2011Closed access

Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis

Regulus Therapeutics (United States) · New York University

PubMed
Indexed incrossrefdoajpubmed

Abstract

Plasma HDL levels have a protective role in atherosclerosis, yet clinical therapies to raise HDL levels have remained elusive. Recent advances in the understanding of lipid metabolism have revealed that miR-33, an intronic microRNA located within the SREBF2 gene, suppresses expression of the cholesterol transporter ABC transporter A1 (ABCA1) and lowers HDL levels. Conversely, mechanisms that inhibit miR-33 increase ABCA1 and circulating HDL levels, suggesting that antagonism of miR-33 may be atheroprotective. As the regression of atherosclerosis is clinically desirable, we assessed the impact of miR-33 inhibition in mice deficient for the LDL receptor (Ldlr-/- mice), with established atherosclerotic plaques.…

Citation impact

684
total citations
FWCI
64.01
Percentile
100%
References
75
Citations per year

Authors

13

Topics & keywords

Keywords
  • Antagonism
  • Reverse cholesterol transport
  • Cholesterol
  • Regression
  • Biology
  • Cell biology
  • Chemistry
  • Medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding